Pethidine Analgesia and Neonatal Hearing Screening Test

Effect of Pethidine Analgesia on False Positivity in Neonatal Hearing Screening Test

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04014504

Enrollment

150

Registered

2019-07-10

Start date

2017-01-01

Completion date

2018-01-01

Last updated

2019-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hearing Loss, Newborn Complication

Keywords

Newborn Hearing Screening, Otoacoustic emissions, Pethidine, False positive

Brief summary

Neonatal hearing screening may fail due to some perinatal and neonatal factors. It is well known that false positivity in newborn hearing screening increases cost and maternal anxiety and anxiety. There is still widespread concern about the use of opoid analgesics to relieve pain during labor. The aim of this study was to determine the effects of pethidine administered during labor on neonatal hearing screening test false positivity rates.

Detailed description

The study group consisted of patients receiving 50 mg intramuscular (I.M) pethidine at the beginning of the active phase of labor and the control group consisted of patients not receiving pethidine. Newborns were evaluated by otoacoustic emission (OAE) test. The OAE test was performed before the patients were discharged. Perinatal and neonatal variables and test results were recorded and the relationship between false positivity and pethidine use was evaluated.

Interventions

DIAGNOSTIC_TESTNeonatal Hearing Screening Test

neonatal hearing screening test results will be evaluated.

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

24 Hours to 14 Days

Healthy volunteers

Inclusion criteria

* term singleton pregnancy, * Gave birth at 37-41 weeks of gestation, * without chronic internal disease, * Pregnant women were included in the study.

Exclusion criteria

* Newborn hospitalized in intensive care, * congenital / chromosomal anomaly, * congenital CMV infection, * facial / ear deformities, * family with hearing problems, * those with hyperbilirunemia, * tested at \<12 hours after birth, * maternal infection, * Diabetes mellitus, recurrent abortion, * smoking, * plesanta previa, * prolonged premature rupture of the membrane (more than 12 hours), epidural -analgesia and * newborns who were at risk of asphyxia hypoxia were excluded from the study.

Design outcomes

Primary

Measure	Time frame	Description
Neonatal Hearing Screening Test	2 week	neonatal hearing screening test results will be evaluated. will be reported as left or passed. The pass'' en response observed in the hearing screening device indicates that the baby passed the screening test, and the refer response indicates that the baby has failed.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026